Advaxis has begun a manufacturing plan for human grade ADXS31-164 for clinical trials. ‘Our 2nd era live Listeria vaccine runs on the novel type of the Her2 antigen,’ said Advaxis EVP of Procedures and Science Dr. John Rothman. ‘It has performed quite well in a number of preclinical models. We desire to be in the clinic shortly with this agent to develop it for several cancer indications.’.. Advaxis publishes research content on Her2 antigen for Listeria vaccine Scientists in Advaxis, Inc., , the live, attenuated Listeria monocytogenes immunotherapy business, had their research using ADXS31-164 recently, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal . We hope to be in the clinic shortly with this agent to develop it for a number of cancer indications.The survivor was discharged from the Ebola treatment device on October 7 and reported no subsequent illness. On September 24 and died the next day She was admitted to an ELWA Ebola treatment unit. The bloodstream sample tested bad for EBOV RNA on quantitative RT-PCR assay, but the sample tested positive for EBOV nucleoprotein-particular and glycoprotein-specific IgG antibodies.8 The semen sample tested positive for EBOV RNA on quantitative RT-PCR assay, but attempts to culture virus were unsuccessful. On April 28 , the survivor provided another semen sample for diagnostic testing at the Liberian National Open public Health Reference Laboratory in Margibi County. No EBOV RNA was detected by the quantitative RT-PCR assay. A timeline of the occasions is shown in Figure 1Amount 1Clinical Timelines for the Patient and the Survivor, from September 2014 through May 2015.